SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Orchid Pharma signs licensing and supply agreement with Pharmasyntez

08 Jul 2026 Evaluate

Orchid Pharma (Orchid) and Pharmasyntez JSC (Pharmasyntez) have entered into a licensing and supply agreement for Exblifep (cefepime/enmetazobactam), a novel combination antibiotic for the treatment of complicated urinary tract infections (cUTI) and hospital-acquired and ventilator-associated bacterial pneumonia (HAP/VAP) caused by Gramnegative bacterial pathogens, subject to regulatory approval by the Ministry of Health of the Russian Federation.

Exblifep is a carbapenem-sparing antibiotic developed to address the growing clinical challenge posed by ESBL-producing Gram-negative bacteria in serious hospital infections. The product is approved by the U.S. Food and Drug Administration (USFDA) and the European Medicines Agency (EMA), is included in IDSA and EUCAST treatment guidelines, and is the first new chemical entity originating from an Indian pharmaceutical company to receive both approvals.

Under the agreement, Pharmasyntez will hold the exclusive rights to register and commercialize Exblifep in Russia, with Orchid supplying the finished dosage form. The partnership represents a potential opportunity of around $178 million over the first 10 years, reflecting the scale of unmet clinical need and the significant hospital procurement volumes in the Russian market.

Orchid Pharma, established as an export-oriented unit (EOU), is a vertically integrated company spanning the entire pharmaceutical value chain from discovery to delivery with established credentials in research, manufacturing and marketing.

Orchid Pharma Share Price

1081.90 -17.75 (-1.61%)
16-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1950.00
Dr. Reddys Labs. 1223.90
Cipla 1429.45
Lupin 2500.05
Zydus Lifesciences 1153.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: